NCT02513563 2026-02-19
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
10 trialsNCT03579316 2026-02-18
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03668340 2026-01-12
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT01164995 2023-09-07
M10MKO
The Netherlands Cancer Institute
Phase 2 Completed
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT05212025 2022-06-14
Adavosertib and Gemcitabine in Advanced Pancreatic
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT03012477 2021-11-23
CISPLATIN + AZD-1775 In Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02593019 2021-03-19
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients
Samsung Medical Center
Phase 2 Completed
NCT02666950 2019-09-06
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Mayo Clinic
Phase 2 Completed
NCT02688907 2018-09-20
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation
Samsung Medical Center
Phase 2 Terminated